{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.03","upperLimit":"7.16","value":"6.250"},{"groupId":"OG001","lowerLimit":"1.85","upperLimit":"5.79","value":"4.670"},{"groupId":"OG002","lowerLimit":"3.23","upperLimit":"9.99","value":"4.840"},{"groupId":"OG003","lowerLimit":"3.49","upperLimit":"7.62","value":"4.800"},{"groupId":"OG004","lowerLimit":"2.60","upperLimit":"4.72","value":"3.320"},{"groupId":"OG005","lowerLimit":"4.25","upperLimit":"4.74","value":"4.640"},{"groupId":"OG006","lowerLimit":"2.46","upperLimit":"8.41","value":"4.840"},{"groupId":"OG007","lowerLimit":"3.71","upperLimit":"8.26","value":"4.370"},{"groupId":"OG008","lowerLimit":"3.51","upperLimit":"12.8","value":"4.770"},{"groupId":"OG009","lowerLimit":"3.32","upperLimit":"4.84","value":"4.240"}]}],"title":"Day 1 (n=6, 9, 23, 13, 4, 3, 22, 22, 15, 13)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.93","upperLimit":"7.88","value":"5.855"},{"groupId":"OG001","lowerLimit":"3.90","upperLimit":"10.8","value":"5.410"},{"groupId":"OG002","lowerLimit":"4.61","upperLimit":"14.3","value":"6.755"},{"groupId":"OG003","lowerLimit":"3.97","upperLimit":"14.1","value":"5.590"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Data was not estimable if evaluable subjects were less than 3 as per the planned decision because only 2 collected values were not sufficient to calculate a reliable estimation.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"3.25","upperLimit":"12.8","value":"5.210"},{"groupId":"OG007","lowerLimit":"4.33","upperLimit":"8.65","value":"5.250"},{"groupId":"OG008","lowerLimit":"4.80","upperLimit":"6.94","value":"5.210"},{"groupId":"OG009","lowerLimit":"3.40","upperLimit":"5.96","value":"4.325"}]}],"title":"Day 15 (n=6, 9, 14, 9, 2, 1, 16, 16, 9, 12)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"24"},{"groupId":"OG008","value":"18"},{"groupId":"OG009","value":"15"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 15 milligram (mg) on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG000","title":"Pimasertib (MSC1936369B) 15mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 30 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG001","title":"Pimasertib (MSC1936369B) 30mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG002","title":"Pimasertib (MSC1936369B) 60mg"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 90 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG003","title":"Pimasertib (MSC1936369B) 90mg"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 45 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG004","title":"Pimasertib (MSC1936369B) 45mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered twice, orally, at a dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DE Cohort).","id":"OG005","title":"Pimasertib (MSC1936369B) 60mg Twice Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG006","title":"TNBC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG007","title":"NSCLC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG008","title":"CRC: Pimasertib 60mg Once Daily"},{"description":"Pimasertib (MSC1936369B) capsule administered at a single oral dose of 60 mg on Day 1 of 21 day cycle until disease progression, intolerable toxicity, Investigator's decision to discontinue treatment, or withdrawal of consent by the subject (DSE Cohort).","id":"OG009","title":"MEL: Pimasertib 60mg Once Daily"}],"paramType":"MEDIAN","populationDescription":"The PK analysis set. Here \"n\" signifies the number of subjects evaluable at the specific time points.","reportingStatus":"POSTED","timeFrame":"Predose 0.5, 1, 1.5, 2, 3, 4, 8 and 24 hour post dose on Day 1, 15 for DSE Cohorts; Predose 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 24 hour post dose on Day 1, 15 for DE cohorts","title":"Half-Life (t1/2) of MSC1936369B (Pimasertib)","type":"SECONDARY","unitOfMeasure":"hour"}